Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014047 | 0.81 | CA1 (0.55) | ACKR3NPC1RAB9AESRRACA1 | |
| SCHEMBL31166241 | 0.79 | P2RY14 (0.48) | NPC1RAB9A | |
| SCHEMBL27166388 | 0.78 | KCNH2 (0.45) | — | |
| SCHEMBL27877288 | 0.77 | ESRRA (0.57) | MAOAMAOBESRRACA1CA2 | |
| SCHEMBL69876 | 0.76 | ESRRA (0.62) | MAOANPC1ESRRACA1CA2 | |
| SCHEMBL2330243 | 0.75 | CA1 (0.57) | MAOAMAOBNPC1RAB9AESRRA | |
| SCHEMBL11902351 | 0.75 | CA1 (0.57) | NPC1RAB9AESRRACA1CA2 | |
| SCHEMBL3477570 | 0.75 | CA1 (0.57) | ACKR3ESRRACA1CA2CA9 | |
| SCHEMBL28801446 | 0.75 | ESRRA (0.60) | MAOANPC1ESRRACA1CA2 | |
| SCHEMBL25123042 | 0.74 | ALKBH2 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | MAOA 4066/4885MAOB 3826/4885ACKR3 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.